{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/restless-legs-syndrome/prescribing-information/pramipexole/","result":{"pageContext":{"chapter":{"id":"ae3af6c6-eb78-5674-a94f-f5f087e5f812","slug":"pramipexole","fullItemName":"Pramipexole","depth":2,"htmlHeader":"<!-- begin field bdca8d17-bde3-47a5-b1a0-2e07d30e8464 --><h2>Pramipexole</h2><!-- end field bdca8d17-bde3-47a5-b1a0-2e07d30e8464 -->","summary":"","htmlStringContent":"<!-- begin item 79bd1e45-1355-4702-b11f-1f6d0869cc43 --><!-- end item 79bd1e45-1355-4702-b11f-1f6d0869cc43 -->","topic":{"id":"ce2c49b0-9c88-5bbe-b742-179c3a41de7d","topicId":"8560b6b4-74c4-48fb-99b2-1738f7bdfc1c","topicName":"Restless legs syndrome","slug":"restless-legs-syndrome","lastRevised":"Last revised in November 2020","chapters":[{"id":"0c5685ed-e78f-5c68-8983-83a722c74100","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6a7ab99-3bce-5334-8352-694d31ef5cc0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"461085e4-b723-57af-8f1a-16da6b5276cd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8a4d8c25-f2fc-5706-989b-f6210f6e1fb8","slug":"changes","fullItemName":"Changes"},{"id":"08d30779-72aa-5609-89bb-35fa111203a1","slug":"update","fullItemName":"Update"}]},{"id":"8544bde0-46f9-502a-aec7-2a5a2d449009","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c04c9edd-95d7-5e3f-94ea-5c7ecd6205a8","slug":"goals","fullItemName":"Goals"},{"id":"4d33d470-bfd2-518f-aebb-b9e86daa02ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ab4dd298-08f9-5497-81cd-0ab7e978b675","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8d907e60-5b96-5b39-a188-b481acc2935a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"330f64fa-36dd-5bd9-847c-b379cdd7b437","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9a4d2e02-acae-5411-92f3-bca31ce98b25","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"877ed575-950a-5933-ae1f-abcee48927b8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"623e0c19-8a9e-5892-b3f3-a72ab9d617ce","slug":"definition","fullItemName":"Definition"},{"id":"f6fe6742-330a-5aea-8b52-b32fc2b3ab48","slug":"causes","fullItemName":"Causes"},{"id":"7a8e05a8-1db9-5aac-9b56-c5be8e7eb9d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"86293e20-8427-58da-8512-93f22162d764","slug":"prognosis","fullItemName":"Prognosis"},{"id":"043ee2a1-37c5-5b2f-8d10-0a9d2d41abe0","slug":"complications","fullItemName":"Complications"}]},{"id":"0ef4212f-c56f-508b-897c-741bceff55bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6836b996-4eee-5e2a-a99b-84973696e8e3","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5ccc9458-1b9d-5fa7-a565-2b00a539b9bd","slug":"assessment","fullItemName":"Assessment"},{"id":"729e434c-5849-59fb-b3ca-e7a86f26a8d6","slug":"investigations","fullItemName":"Investigations"},{"id":"0ce4b1b3-2e3a-5901-8e9c-981cea4198d7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7a12e175-49ce-5c68-9c8f-756159646a3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"33ccae89-80e7-572a-b148-a81c781d0956","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3af6c6-eb78-5674-a94f-f5f087e5f812","slug":"pramipexole","fullItemName":"Pramipexole"},{"id":"1664194f-800a-54c6-bd79-106678653aaa","slug":"ropinirole","fullItemName":"Ropinirole"},{"id":"1a0b2fc3-18c3-51a9-968c-88bb51f2637f","slug":"rotigotine","fullItemName":"Rotigotine"},{"id":"87f55f71-dd3d-5e97-9c88-5fe3a78503db","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"a931371b-564c-5833-b5b4-d21ad3f1a361","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"6590cad9-132e-548c-b7ad-bf4375ef2caf","slug":"codeine","fullItemName":"Codeine"},{"id":"70676cc9-d1a4-5639-a227-62e452e13b2b","slug":"benzodiazepines-z-drugs","fullItemName":"Benzodiazepines and Z-drugs"},{"id":"fe9dc2de-9fbe-527f-b34b-446254f3d127","slug":"augmentation","fullItemName":"Augmentation"},{"id":"2203998a-e9f3-59c3-9132-50418bf47566","slug":"loss-of-efficacy","fullItemName":"Loss of efficacy"},{"id":"7d279d8d-8d6c-5c7d-8597-6ee343a7a574","slug":"impulse-control-disorders","fullItemName":"Impulse control disorders"}]},{"id":"0fadb6b8-91c2-57be-8c1d-2d3e31da6d60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"afa91ee5-1f42-5cc6-b9ec-6ef16749457d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"baf472ab-f0f9-518a-8310-81583fd7d905","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d31c719-7426-52cb-8343-b11a7bb8b5b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a915b18c-93a0-5269-8ff1-021677ba9dd3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e85726f-b5ea-5c2c-a886-f74ab46fbc6b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8ac2285b-b086-5b54-98d6-0ec8c43f05c2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a058ec2-b2e0-5618-b51f-27102b964d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"17255e41-ac9e-5dff-9ac1-8291bc8b7738","slug":"doses","fullItemName":"Doses","depth":3,"htmlHeader":"<!-- begin field b51d8cb8-9939-43c1-b753-c2a4ceeee2f7 --><h3>What doses of pramipexole are indicated for restless legs syndrome?</h3><!-- end field b51d8cb8-9939-43c1-b753-c2a4ceeee2f7 -->","summary":"","htmlStringContent":"<!-- begin item 4c466806-d375-4182-bbbe-fabb8bfde3a4 --><!-- begin field 56b6a61c-4a33-486c-b99b-909948655888 --><ul><li><strong>Initial dose:</strong> 88 micrograms pramipexole base (125 micrograms pramipexole salt) 1–2 hours before bedtime (or anticipated onset of symptoms).</li><li><strong>Titration:</strong> increase if needed by 88 micrograms pramipexole base (125 micrograms pramipexole salt) after every 4–7 days.</li><li><strong>Maximum recommended dose:</strong> 540 micrograms pramipexole base (750 micrograms pramipexole salt) daily.</li><li>The manufacturer advises that prescribers should avoid abrupt discontinuation of pramipexole. They recommend slow withdrawal of this dopaminergic therapy in order to avoid neuroleptic malignant syndrome or dopamine agonist withdrawal syndrome.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field 56b6a61c-4a33-486c-b99b-909948655888 --><!-- end item 4c466806-d375-4182-bbbe-fabb8bfde3a4 -->","subChapters":[]},{"id":"af9b87e8-fd87-5afa-8ca9-734e7c6136c3","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 3eac29ee-b00d-489f-97fb-6dcd80481ae8 --><h3>What are the contraindications for pramipexole?</h3><!-- end field 3eac29ee-b00d-489f-97fb-6dcd80481ae8 -->","summary":"","htmlStringContent":"<!-- begin item f1cde112-a037-4657-b0e6-c4556b720527 --><!-- begin field a3e4af84-4238-4080-aa57-52e4cc4b7f69 --><ul><li><strong>Do not prescribe pramipexole for restless legs syndrome to:</strong><ul><li>Pregnant or breastfeeding women.</li><li>People with hypersensitivity to pramipexole or to any constituent in the tablet.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field a3e4af84-4238-4080-aa57-52e4cc4b7f69 --><!-- end item f1cde112-a037-4657-b0e6-c4556b720527 -->","subChapters":[]},{"id":"5395b5d3-d1fb-5648-8a2e-ed958a038b6b","slug":"cautions","fullItemName":"Cautions","depth":3,"htmlHeader":"<!-- begin field c8895a1d-2e15-4e64-a166-11f47e2aa501 --><h3>What are the cautions when using pramipexole?</h3><!-- end field c8895a1d-2e15-4e64-a166-11f47e2aa501 -->","summary":"","htmlStringContent":"<!-- begin item 482c27cf-f7de-4da7-89b8-bcb68b7812fa --><!-- begin field db2264aa-c952-42a3-af7b-79bc3769373b --><ul><li><strong>Driving and using machinery</strong><ul><li>Pramipexole causes somnolence and episodes of sudden sleep onset in some people, and, uncommonly, without awareness or warning.</li><li>People should exercise caution while driving or operating machines, and must not drive or operate machinery if they experience episodes of sudden sleep onset.</li><li>The dose should be reduced or the drug stopped completely if sudden sleep onset occurs.</li><li>Also, exercise caution if taking other sedating drugs or alcohol in combination with pramipexole.</li></ul></li><li><strong>Psychotic disorders</strong><ul><li>Mania, delirium, and hallucinations may occur in people treated with pramipexole.</li><li>People with psychotic disorders should only be treated with pramipexole if the potential benefits outweigh the risks.</li><li>Co-administration of antipsychotic drugs with pramipexole should be avoided.</li></ul></li><li><strong>Visual disturbances</strong><ul><li>Visual disturbances such as double vision and difficulty focussing have been reported. The manufacturers of pramipexole recommend ophthalmologic monitoring at regular intervals or if vision abnormalities occur.</li></ul></li><li><strong>People with severe cardiovascular disease</strong><ul><li>Blood pressure monitoring, especially at the beginning of treatment, is recommended owing to the risk of postural hypotension associated with dopaminergic therapy.</li></ul></li><li><strong>Renal impairment</strong><ul><li>The dose may need to be reduced in people with renal impairment. See the Summary of Product Characteristics for details.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field db2264aa-c952-42a3-af7b-79bc3769373b --><!-- end item 482c27cf-f7de-4da7-89b8-bcb68b7812fa -->","subChapters":[]},{"id":"3f385753-289d-55d0-bcb8-5460b0e374ff","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 8d35ff48-f202-4b2e-88bd-da64d60c5ef6 --><h3>What drug interactions are associated with pramipexole?</h3><!-- end field 8d35ff48-f202-4b2e-88bd-da64d60c5ef6 -->","summary":"","htmlStringContent":"<!-- begin item 630ec743-4242-4266-99e9-c00c9b8a591c --><!-- begin field 03cfa20a-1339-4d86-a943-121c40ab6ed7 --><ul><li><strong>The manufacturer of pramipexole advises avoiding concomitant use of antipsychotic drugs </strong>owing to antagonism of effect.</li><li><strong>Cimetidine has been demonstrated to reduce the renal clearance of pramipexole.</strong><ul><li>Theoretically, other drugs with similar renal clearance mechanism may also be affected in a similar way, such as amantadine, mexiletine, zidovudine, cisplatin, quinine, and procainamide.</li><li>The clinical significance of these possible interactions are not clear but the manufacturer recommends a dose reduction of pramipexole if used concomitantly with these other drugs.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Preston, 2020</a>]</p><!-- end field 03cfa20a-1339-4d86-a943-121c40ab6ed7 --><!-- end item 630ec743-4242-4266-99e9-c00c9b8a591c -->","subChapters":[]},{"id":"dd03db3b-0ec1-5da2-aebc-4b326fbea9c6","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field aea7a46d-aea9-440b-b9b1-5d0ea225106a --><h3>What are the adverse effects of pramipexole?</h3><!-- end field aea7a46d-aea9-440b-b9b1-5d0ea225106a -->","summary":"","htmlStringContent":"<!-- begin item 9afbab5e-d520-4342-8c55-6bbe1e6d2ed7 --><!-- begin field eea880d7-04a6-4f86-a2e7-fa9a4ecb075a --><ul><li><strong>The most commonly reported adverse drug reactions </strong>are nausea, headache, dizziness, and fatigue.</li><li><strong>Less common but important adverse drug reactions </strong>include hallucinations, mania, delusions, sudden somnolence or drowsiness, visual disturbances, <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/augmentation/\">augmentation</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/restless-legs-syndrome/prescribing-information/impulse-control-disorders/\">impulse control disorders</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BNF, 2020</a>]</p><!-- end field eea880d7-04a6-4f86-a2e7-fa9a4ecb075a --><!-- end item 9afbab5e-d520-4342-8c55-6bbe1e6d2ed7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}